Document is current
Any future updates will be listed below
-
Authors
Peelaerts, Wouter https://orcid.org/0000-0003-3776-4162
Mercado, Gabriela
George, Sonia
Villumsen, Marie
Kasen, Alysa
Aguileta, Miguel
Linstow, Christian
Sutter, Alexandra B.
Kuhn, Emily
Stetzik, Lucas
Sheridan, Rachel
Bergkvist, Liza
Meyerdirk, Lindsay
Lindqvist, Allison
Gavis, Martha L. Escobar
Van den Haute, Chris
Hultgren, Scott J.
Baekelandt, Veerle
Pospisilik, J. Andrew
Brudek, Tomasz
Aznar, Susana
Steiner, Jennifer A.
Henderson, Michael X.
Brundin, Lena
Ivanova, Magdalena I.
Hannan, Tom J.
Brundin, Patrik
-
Funding
Funding for this research was provided by:
Fulbright Association
American Parkinson's Disease Foundation
Fonds Wetenschappelijk Onderzoek
- License Information
-
More Information
Article History
Received: 30 December 2022
Revised: 28 February 2023
Accepted: 13 March 2023
First Online: 30 March 2023
Declarations
:
: W.P. has received support as a consultant from Roche. P.B. has received support as a consultant from Calico Life Sciences, CuraSen, Enterin Inc, Idorsia Pharmaceuticals, Lundbeck A/S, AbbVie, Fujifilm-Cellular Dynamics International, and Axial Therapeutics. He has received commercial support for research from Lundbeck A/S and F. Hoffman-La Roche. He has ownership interests in Acousort AB, Axial Therapeutics, Enterin Inc, Roche and RYNE Biotechnology. During the time that this paper was undergoing revision, he became an employee of F. Hoffman-La Roche, although none of the data was generated by this company. All the other authors declare no additional competing financial interests. The other authors declare that they have no competing interests.
